Inrig Jula
Known title: Chief Medical OfficerCIK: 0001902368
Associated companies
Transaction History
| TVTX | ▲ Buy | Option Exercise | 32,395 | $289K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 25,390 | $1.6M | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 17,284 | $1.1M | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,600 | $102K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 400 | $26K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Gift | 468 | $0 | 6/22/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 311 | $14K | 5/6/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,174 | $101K | 5/5/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 4,250 | $0 | 5/4/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 20,000 | $448K | 5/4/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 20,000 | $900K | 5/4/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,018 | $43K | 4/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 7,215 | $303K | 4/14/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 14,000 | $0 | 4/13/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,547 | $50K | 2/4/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 232 | $8K | 2/4/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 6,956 | $223K | 2/3/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 28,130 | $0 | 1/31/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 445 | $17K | 1/6/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,031 | $82K | 1/5/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 15,000 | $134K | 12/24/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 15,000 | $630K | 12/24/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 815 | $12K | 7/1/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,568 | $60K | 2/12/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 8,000 | — | 2/10/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,066 | $21K | 2/4/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 4,207 | $85K | 2/3/2025 | View on chart |
| TVTX | ▲ Buy | Grant | 30,000 | $0 | 1/31/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 440 | $8K | 1/6/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,066 | $39K | 1/3/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 684 | $9K | 9/10/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,191 | $25K | 9/9/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 6,750 | $0 | 9/5/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,174 | $19K | 2/1/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 25,000 | $0 | 1/31/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 440 | $4K | 1/4/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,069 | $20K | 1/3/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 20,250 | $0 | 1/31/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 442 | $9K | 1/5/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,051 | $43K | 1/4/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 20,000 | $0 | 1/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data
Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.